GRAIL, Inc., a commercial-stage healthcare company, focuses on developing technologies for early cancer detection in the United States and internationally. It provides Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company offers development services including support for ongoing clinical studies, pilot testing, research, and therapy development. It also develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.

GRAIL Inc.

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Gilead Sciences (GILD – Research Report) and GRAIL I...

Market Cap	$2.97B	P/E Ratio	N/A
52W High	$118.84	52W Low	$20.44
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-16.0%	52W Position	84.6%
Overall Score	52	Value Score	60
Quality Score	47	Technical Score	50

EPS Current Est	$-12.09	EPS Next Est	$-11.75
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	GRAL	$103.67	+5.98%	489.28K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	GRAL	$103.67	+6.0%	489.28K
3
4
5
6

GRAL

GRAL

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get GRAIL Inc. Data in Excel

Get GRAIL Inc. Data in Excel